Corporate Social Responsibility
At Diabetology, our reason for existing is to reduce the burden of metabolic disease on people, families, and health systems globally — through oral therapies that are safer, more accessible, and more equitable than anything currently available.
537M
1 in 8
5%
80%
Our Purpose
The global metabolic disease epidemic — diabetes, obesity, cardiovascular disease, and their downstream consequences including blindness, amputation, kidney failure, and premature death — falls most heavily on the world’s most underserved populations. Current injectable therapies are expensive, burdensome, and inaccessible to the majority of those who need them. We believe oral therapy is not a convenience — it is an equity issue.
“The question we ask ourselves every day is not just whether our science works — but whether it can actually reach the people who need it most. An oral insulin capsule that costs a fraction of an injector and requires no cold chain is not just a better product. It is a different kind of promise.”
— Glen Travers, Executive Chairman & Co-Founder, Diabetology Ltd
Our Framework
Our CSR programme is built around four interconnected commitments that reflect the social, scientific, environmental, and ethical dimensions of our work.
We design our programmes from the outset for access in low- and middle-income countries. By using off-patent APIs, room-temperature capsule technology, and a low-cost manufacturing model, we ensure that the populations bearing the greatest burden of metabolic disease are not priced out of treatment.
Potential Impact
537M
People with diabetes who could benefit from an oral insulin option
50M+
$0.75
Commitments in Practice
1
Our Capsulin oral insulin and Oraglutide programmes are structured to launch first in India and other markets where semaglutide is now off-patent, at price points accessible to the middle-income population — not reserved for high-income healthcare systems.
2
We publish our data — positive and negative — at peer-reviewed congresses (ADA, EASD) and in indexed journals. Our Phase 2b Capsulin data is published in Diabetes, Obesity & Metabolism (2022). Our Oraglutide first-in-human data was presented as an oral at ADA 2026.
3
Needle phobia affects an estimated 25% of people with diabetes, contributing to delayed insulin initiation and poor outcomes. Every Diabetology product is designed for oral delivery — removing the needle entirely as a barrier to care.
4
Two-thirds of weight lost on GLP-1 therapy is regained within 12 months of stopping — a silent epidemic that worsens cardiometabolic risk for millions who can no longer afford or tolerate ongoing therapy. Our Satietyde™ microdose programme is specifically designed to address this underserved and growing population.
5
The insulin cold chain generates significant refrigeration emissions throughout manufacture, storage, and distribution. Our room-temperature oral capsule technology eliminates this requirement for the end product, reducing the per-patient environmental cost of treatment.
6
Our collaborative research model with the Universities of Cambridge, Swansea, and Western Australia (Telethon Kids Institute) ensures that our science is validated by independent centres of excellence rather than only by in-house data — the gold standard for responsible biomedical research.
7
Emerging evidence — supported by our Satietyde programme — suggests that low-level GLP-1 receptor stimulation may attenuate alcohol craving, drug craving, and reward-seeking behaviours via mesolimbic dopamine pathways. We include these exploratory endpoints in our Phase 2a trial, recognising the profound social cost of addiction disorders in parallel with metabolic disease.
8
Our Phase 2a studies are conducted at multi-national sites including Canada and India, ensuring that the evidence base for our products reflects the global diversity of the populations we aim to serve — not only Western, high-income populations.
UN Sustainable Development Goals
Our work directly contributes to several of the United Nations Sustainable Development Goals (SDGs), recognising that metabolic disease is not solely a medical challenge but a social, economic, and environmental one.
SDG 3 — Good Health & Wellbeing
SDG 10 — Reduced Inequalities
SDG 12 — Responsible Consumption
SDG 13 — Climate Action
SDG 17 — Partnerships for the Goals
Research Partnerships
Diabetology’s science is validated through partnerships with globally recognised research institutions — ensuring independence, rigour, and breadth of expertise that no single company can sustain alone.
🎓 University of Cambridge
🎓 Swansea University (Prifysgol Abertawe)
🎓 University of Western Australia
📱 Telethon Kids Institute
📱 Baker Heart & Diabetes Institute, Melbourne
📱 JSS Medical Research, Canada
📱 Cardinal Bioresearch, Queensland
🏛 London BioScience Innovation Centre
Whether you are a researcher, healthcare partner, investor, or patient advocate — if you share our belief that better oral therapy for metabolic disease is both possible and urgently needed, we want to hear from you.
Oral Capsule Technology for Insulin, GLP-1 and Other Protein-Based Therapies and Combinations.
Copyright © 2026 Diabetology Ltd. All rights reserved.
